Is Maravai LifeSciences Holdings, Inc. (MRVI) a Buy, Sell, or Hold?
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$6.51 USD
$0.15 (2.36%)
- Volume
- 6.44M
- Average Volume
- 2.82M
- Market Capitalization
- $1.8B
- P/E Ratio
- -8.97
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $6.64
- Year Low
- $1.99
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.91
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Bernd Brust |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MRVI |
| CUSIP | 56600D107 |
| CIK | 0001823239 |
| Web | https://www.maravai.com |
| Phone | 858 546 0004 |
| Currency | USD |
| Employees | 416 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.28 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.91 |
| Quick Ratio | 4.96 |
| Cash Ratio | 3.89 |
Sales & Book Value
| Annual Sales | $185.74M |
| Price / Sales | 8.78 |
| Cash Flow | -0.35 |
| Price / Cash Flow | -34.67 |
| Price / Book | 4.51 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | 8.50% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.91 |
| Trailing P/E Ratio | -8.97 |
| PEG Ratio | -0.37 |
| P/E Growth | -0.37 |
| Net Income | $-130.77M |
| Net Margin | -51.07% |
| Pretax Margin | -92.22% |
| Return on Equity | -44.72% |
| Return on Assets | -14.66% |
Financials Score
| AltmanZ Score | 2.96 |
| Piotroski Score | 4.00 |
| Working Capital | 209.11M |
| Total Assets | 713.22M |
| Ebit | -162.85M |
| Market Cap | 1.76B |
| Total Liabilities | 344.13M |
Poll Results
About Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside c ... hemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
2026-06-16 09:02:00
TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to h
2026-06-16 08:30:00
JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo.
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
2026-06-03 08:30:00
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
2026-05-18 16:00:00
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
2026-05-18 16:00:00
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable
2026-05-18 10:19:09
Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings.
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
2026-05-10 11:57:49
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences Q1 Earnings Call Highlights
2026-05-08 16:10:17
Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.
Frequently Asked Questions
-
What is the current Maravai LifeSciences Holdings, Inc. (MRVI) stock price?
-
Maravai LifeSciences Holdings, Inc.(NASDAQ:MRVI) stock price is $6.51 in the last trading session. During the trading session, MRVI stock reached the peak price of $6.635 while $1.99 was the lowest point it dropped to. The percentage change in MRVI stock occurred in the recent session was 2.36% while the dollar amount for the price change in MRVI stock was $0.15.
-
MRVI's industry and sector of operation?
-
The NASDAQ listed MRVI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MRVI?
-
Kurt Oreshack | Executive Vice President, General Counsel & Secretary
Christine Dolan | Executive Vice President & GM of Cygnus Technologies
Judith A. Solecki | Senior VP & Chief Human Resources Officer
Bernd Brust | Chief Executive Officer & Director
Chad Decker | Senior Vice President of Sales at TriLink & Alphazyme -
How many employees does MRVI have?
-
Number of MRVI employees currently stands at 416. MRVI operates from 10770 Wateridge Circle, San Diego, CA 92121, US.
-
Link for MRVI official website?
-
Official Website of MRVI is: https://www.maravai.com
-
How do I contact MRVI?
-
MRVI could be contacted at phone #858 546 0004 and can also be accessed through its website. MRVI operates from 10770 Wateridge Circle, San Diego, CA 92121, US.
-
How many shares of MRVI are traded daily?
-
The average number of MRVI shares traded daily for last 3 months was 2.82M.
-
What is the market cap of MRVI currently?
-
The market value of MRVI currently stands at $1.8B with its latest stock price at $6.51